MOLECULAR AND CELLULAR PATHOGENESIS OF HUMAN LIVER DISEASE

人类肝脏疾病的分子和细胞发病机制

• 批准号: nhmrc : 358398
• 负责人: Prof Geoffrey Farrell
• 金额: $ 328.62万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Programs
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-cellular-pathogenesis-liver-disease/95434
• 关键词: MOLECULAR; CELLULAR; PATHOGENESIS; HUMAN; LIVER

n humans, chronic liver diseases cause cirrhosis of the liver in some but not all individuals. This leads to protracted ill-health, complications (fluid retention in the abdomen, confusion, bloodstream infections, kidney failure, liver cancer) resulting in hospitalisation, liver transplantation and premature death. In Australia, cirrhosis is an important cause of death and of years of potential life lost, while liver cancer has recently doubled and is predicted to treble by 2020. The common causes are hepatitis C, fatty liver disorders, alcohol and hepatitis B; when 2 of these are present together, there is a higher risk of cirrhosis. This program aims to unravel the pathological processes which cause cirrhosis at the molecular and cellular levels, in order to understand why some people are at higher risk. These processes could result from genetic predisposition, other constitutional factors (age, gender) or from lifestyle factors (overnutrition, inactivity, alcohol). The 3 chief investigators from Westmead s Millennium Institute and the Centenary Institute of Royal Prince Alfred Hospital are international experts in hepatitis C, non-alcoholic steatohepatitis (NASH) and other fatty liver disorders, autoimmune hepatitis, liver transplantation, and scarring processes that lead to cirrhosis of the liver. The new knowledge that will result from these studies will be used to help prevent people developing severe forms of chronic liver disease, and for treating cirrhosis if it has already occurred.

在人类中，慢性肝病在一些但不是所有个体中引起肝硬化。这会导致长期的健康状况不佳、并发症（腹部液体潴留、意识模糊、血液感染、肾衰竭、肝癌），导致住院、肝移植和过早死亡。在澳大利亚，肝硬化是死亡和潜在寿命损失的重要原因，而肝癌最近增加了一倍，预计到2020年将增加两倍。常见的原因是丙型肝炎、脂肪肝、酒精和B型肝炎;当其中2种同时存在时，肝硬化的风险更高。该计划旨在揭示在分子和细胞水平上导致肝硬化的病理过程，以了解为什么有些人处于较高的风险。这些过程可能是由遗传易感性、其他体质因素（年龄、性别）或生活方式因素（营养过剩、不活动、酒精）造成的。来自Westmead千禧研究所和皇家阿尔弗雷德王子医院百年研究所的3名首席研究员是丙型肝炎，非酒精性脂肪性肝炎（NASH）和其他脂肪肝疾病，自身免疫性肝炎，肝移植和导致肝硬化的瘢痕形成过程的国际专家。从这些研究中获得的新知识将用于帮助预防人们患上严重的慢性肝病，并用于治疗已经发生的肝硬化。